Search clinical trials for: BGB-45035

Total 232 results

BeiGene

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035

Autoimmune Diseases | Healthy Volunteers | Healthy Subjects | Healthy Participants | Healthy Adult Participants

Australia
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BerGenBio ASA

Terminated

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Brain and Central Nervous System Tumors

United States
BeiGene

Completed

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

Healthy Volunteers

United States
BeiGene

Completed

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Healthy

Australia
BeiGene

Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (MAGNOLIA)

Marginal Zone Lymphoma | MZL

China, Australia, Italy, France, New Zealand, Czechia, United Kingdom, United States, Korea, Republic of
BeiGene

Completed

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Covid19

United States, Mexico, Brazil, South Africa
BeiGene
Myriad Genetic Laboratories, Inc.

Completed

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Spain, United Kingdom, France, Australia, New Zealand
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, Belgium, France, Brazil, Ireland, Czechia, Romania, Portugal, Georgia, Argentina, Poland, Puerto Rico, Austria, Switzerland
Fudan University

Recruiting

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Limited Stage Small Cell Lung Cancer

China
BeiGene

Recruiting

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

China
BeiGene

Completed

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Locally Advanced or Metastatic Urothelial Bladder Cancer

Korea, Republic of, China
BeiGene

Completed

First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants

Not Determined

Australia, China
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
BeiGene

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Australia New Zealand Gynaecological Oncology Group
BeiGene

Withdrawn

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE)

Ovarian Cancer | Carcinosarcoma
BeiGene

Terminated

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Advanced Solid Tumors

Australia, Spain, New Zealand
BeiGene

Completed

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Australia
BeiGene

Completed

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Solid Tumors

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors

Australia, New Zealand
BeiGene

Recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)

United States, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
BeiGene

Active, not recruiting

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

Mature B-cell Malignancies

China
BeiGene

Withdrawn

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
BeiGene
SpringWorks Therapeutics, Inc.

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Solid Tumor, Adult

Australia, United States
BeiGene

Active, not recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States
BeiGene

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasm

China, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
BeiGene

Active, not recruiting

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Solid Tumor

Australia, United States
BeiGene

Withdrawn

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Solid Tumors
SpringWorks Therapeutics, Inc.

Recruiting

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Advanced Solid Tumor

United States, Australia
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
BeiGene

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors

China
BerGenBio ASA

Terminated

A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Ovarian Neoplasms

Korea, Republic of, Singapore, United Kingdom, Norway
BerGenBio ASA

Completed

A First-time-in-human Study of BGB149

Healthy Volunteers

United Kingdom
BeiGene

Completed

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Advanced Cancer

United States, Taiwan, Australia, Korea, Republic of, New Zealand
West China Hospital

Recruiting

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Thyroid Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
BeiGene

Recruiting

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Solid Tumor | Advanced Solid Tumor | Metastatic Solid Tumor

United States, France, Australia
BeiGene

Recruiting

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China, United States, Australia, New Zealand, Korea, Republic of
BeiGene

Enrolling by invitation

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Korea, Republic of, Turkey
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
BeiGene

Recruiting

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Advanced Solid Tumors

United States, Australia, Spain
BeiGene

Completed

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Advanced or Inoperable Gastric Cancer

United States, Hungary, Spain, China, Hong Kong, Japan, Australia, Taiwan, Belgium, Czechia, Singapore, France, Poland, United Kingdom, Romania, Russian Federation, Georgia
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, Spain, France, Italy, Korea, Republic of, Poland
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
BeiGene

Completed

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Covid19

Australia
BeiGene

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Lymphoma | Leukemia

China, Australia
Novartis Pharmaceuticals

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer

Search clinical trials for: BGB-45035

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations